Literature DB >> 17656092

Cytotoxic small molecule dimers and their inhibitory activity against human breast cancer cells.

M Kyle Hadden1, Brian S J Blagg.   

Abstract

Small molecules based upon natural product dimers that exhibit cytotoxic activity were synthesized and evaluated for their anti-proliferative activity in human breast cancer cell lines. A central isophthalic core structure linking aromatic amines containing 3,5-disubstitutions produced the most active compounds. This series of compounds was found to be more active against the estrogen receptor positive cell line MCF-7 than the estrogen receptor negative cell line, SKBr3.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17656092      PMCID： PMC2682424          DOI： 10.1016/j.bmcl.2007.07.014

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  18 in total

Review 1.  Receptor signaling: when dimerization is not enough.

Authors:  G Jiang; T Hunter
Journal:  Curr Biol       Date:  1999 Jul 29-Aug 12       Impact factor: 10.834

2.  High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase.

Authors:  Lakshmi Galam; M Kyle Hadden; Zeqiang Ma; Qi-Zhuang Ye; Bo-Geon Yun; Brian S J Blagg; Robert L Matts
Journal:  Bioorg Med Chem       Date:  2007-01-04       Impact factor: 3.641

3.  Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery.

Authors:  Joseph A Burlison; Brian S J Blagg
Journal:  Org Lett       Date:  2006-10-12       Impact factor: 6.005

Review 4.  Structural basis for cytokine hormone-receptor recognition and receptor activation.

Authors:  A A Kossiakoff; A M De Vos
Journal:  Adv Protein Chem       Date:  1998

5.  Cooperativity and dimerization of recombinant human estrogen receptor hormone-binding domain.

Authors:  M E Brandt; L E Vickery
Journal:  J Biol Chem       Date:  1997-02-21       Impact factor: 5.157

6.  Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy.

Authors:  Gary H Posner; Ik-Hyeon Paik; Surojit Sur; Andrew J McRiner; Kristina Borstnik; Suji Xie; Theresa A Shapiro
Journal:  J Med Chem       Date:  2003-03-13       Impact factor: 7.446

Review 7.  Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.

Authors:  Brian S J Blagg; Timothy D Kerr
Journal:  Med Res Rev       Date:  2006-05       Impact factor: 12.944

8.  Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor.

Authors:  C Wiesmann; G Fuh; H W Christinger; C Eigenbrot; J A Wells; A M de Vos
Journal:  Cell       Date:  1997-11-28       Impact factor: 41.582

9.  Bivalent ligands as probes of estrogen receptor action.

Authors:  K E Bergmann; C H Wooge; K E Carlson; B S Katzenellenbogen; J A Katzenellenbogen
Journal:  J Steroid Biochem Mol Biol       Date:  1994-06       Impact factor: 4.292

10.  Antimalarial and antitumor evaluation of novel C-10 non-acetal dimers of 10beta-(2-hydroxyethyl)deoxoartemisinin.

Authors:  J Prince Jeyadevan; Patrick G Bray; James Chadwick; Amy E Mercer; Aoife Byrne; Stephen A Ward; B Kevin Park; Dominic P Williams; Rick Cosstick; Jill Davies; Adrian P Higson; Ed Irving; Gary H Posner; Paul M O'Neill
Journal:  J Med Chem       Date:  2004-02-26       Impact factor: 7.446
View more
  2 in total

1.  Potent inhibitors of hepatitis C core dimerization as new leads for anti-hepatitis C agents.

Authors:  Feng Ni; Smitha Kota; Virginia Takahashi; A Donny Strosberg; John K Snyder
Journal:  Bioorg Med Chem Lett       Date:  2011-04-15       Impact factor: 2.823

Review 2.  Dimeric approaches to anti-cancer chemotherapeutics.

Authors:  M K Hadden; B S J Blagg
Journal:  Anticancer Agents Med Chem       Date:  2008-10       Impact factor: 2.505
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.